Iovance Biotherapeutics
Logotype for Iovance Biotherapeutics Inc

Iovance Biotherapeutics (IOVA) investor relations material

Iovance Biotherapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Iovance Biotherapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Commercial launch and market opportunity

  • Q3 2026 sales reached $122M for AMTAGVI and PROLEUKIN; FY 2025 sales were $264M, and 9M 2026 revenue was $292M.

  • ATC expansion remains a priority; at least 110 centers are targeted by year-end 2026, with management on track to meet or exceed that goal.

  • U.S. second-line-plus metastatic melanoma represents ~8,500 patients; first-line melanoma exceeds 22,000, while non-squamous lung market potential is 7x melanoma’s.

  • AMTAGVI is approved in the U.S., Canada and Australia; Switzerland and U.K. approvals are expected in Q1 2027, with an EU resubmission planned.

  • Philadelphia manufacturing can scale through existing modular capacity; cryopreserved product has a 12-month shelf life, and new facilities are not in immediate plans.

Financial outlook and operations

  • FY 2026 revenue guidance is $410M–$420M; management said it feels in good shape and expects continued growth from treating more patients.

  • Q3 gross margin was 60%, with 9M margin at 54%; long-term goal remains 70% or higher, without a specified timeframe.

  • Cost control and plant efficiencies are supporting margin improvement; quarterly results may vary, while management expects longer-term progress.

  • January 1, 2027 price increases: 9% for AMTAGVI and 7% for PROLEUKIN; reported cash balance was $382M at the end of the last reported quarter.

  • Prior plant upgrades are expected to prevent routine maintenance from disrupting production; clinical trials and operating expenses are being managed with financial discipline.

Melanoma development

  • Phase III TILVANCE-301 serves as the U.S. accelerated-approval confirmatory trial and supports potential first-line accelerated and eventual confirmatory approvals; enrollment is well underway.

  • Recent first-line phase II data showed an ORR above 60% and a notably high complete-response rate; final data cut is complete and a manuscript is in preparation.

  • Management plans to share more melanoma data; second-line patients treated with two or fewer prior lines had response rates above 50%, and five-year data showed median overall survival exceeding 36 months.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Iovance Biotherapeutics earnings date

Logotype for Iovance Biotherapeutics Inc
Q4 202624 Feb, 2027
Iovance Biotherapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Iovance Biotherapeutics earnings date

Logotype for Iovance Biotherapeutics Inc
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Iovance Biotherapeutics Inc is a biotechnology company focused on developing cell-based immunotherapies for the treatment of cancer. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harnessing and enhancing a patient's immune cells to target and destroy cancer cells. Iovance’s research primarily targets solid tumors, aiming to offer new treatment options for patients with melanoma, cervical cancer, and other types of cancers. Its therapies are developed using advanced cell therapy technologies to address cancers that are resistant to traditional treatments. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.